Tumor genomes are mosaics of somatic structural variants (SVs) that may contribute to the activation of oncogenes or inactivation of tumor suppressors, for example, by altering gene copy number amplitude. However, there are multiple other ways in which SVs can modulate transcription, but the general impact of such events on tumor transcriptional output has not been systematically determined. Here we use whole-genome sequencing data to map SVs across 600 tumors and 18 cancers, and investigate the relationship between SVs, copy number alterations (CNAs), and mRNA expression. We find that 34% of CNA breakpoints can be clarified structurally and that most amplifications are due to tandem duplications. We observe frequent swapping of strong and weak promoters in the context of gene fusions, and find that this has a measurable global impact on mRNA levels. Interestingly, several long noncoding RNAs were strongly activated by this mechanism. Additionally, SVs were confirmed in telomere reverse transcriptase (TERT) upstream regions in several cancers, associated with elevated TERT mRNA levels. We also highlight high-confidence gene fusions supported by both genomic and transcriptomic evidence, including a previously undescribed paired box 8 (PAX8)-nuclear factor, erythroid 2 like 2 (NFE2L2) fusion in thyroid carcinoma. In summary, we combine SV, CNA, and expression data to provide insights into the structural basis of CNAs as well as the impact of SVs on gene expression in tumors.
cancer genomics | somatic structural variation | gene fusion | gene expression S omatic structural variants (SVs) in genomic DNA can lead to changes in gene copy number, which may contribute to tumor development by altering gene expression levels (1) . Several studies have tried to systematically investigate the effect of copy number alterations (CNAs) on tumor transcriptomes (2, 3) , but this can only explain part of the expression changes observed in tumors. Notably, there are several other mechanisms by which SVs can alter tumor transcriptional output, including creation of fusion genes. These may produce chimeric mRNAs encoding novel oncogenic proteins (4, 5) or, alternatively, fusion mRNAs that maintain their protein-coding sequence while being transcriptionally induced or repressed due to swapping of 5′ ends, including the promoter (6) . Additionally, SVs can affect mRNA levels by bringing distant regulatory elements into the proximity of transcription start sites (TSSs) without structurally altering the mRNA (7) . More systematic investigations of the impact of SVs on gene expression levels in tumors are, however, lacking, in part due to the fact that mapping of SVs is considerably more challenging compared with determining CNA profiles. Additionally, although CNAs arise as a result of SVs, the two have generally been studied in isolation and the general structural basis of somatic CNAs in tumors is poorly investigated.
Recent studies have started to use whole-genome sequencing (WGS) to identify SVs in tumors, and multiple tools have been published (8) (9) (10) (11) (12) . These are based on the idea that breakpoints should reveal themselves on the basis of discordant read pairs (13) or split reads mapping partially to both ends of fused chromosomal segments (14) . Several factors complicate the analysis, in particular mappability issues due to repetitive sequence regions (15) . Indeed, it has become clear that the results produced by different methods are not consistent, and some studies have intersected multiple approaches to provide a presumed high-confidence set of predictions (16, 17) . Adding to the challenges is the difficulty of assessing performance: True positive sets have thus far been obtained through simulated genomic sequences (18) , but this will not reflect the true complexity of cancer genomes. Improved benchmarking is thus desirable before SVs can be comprehensively studied with WGS in human cancers.
Here, enabled by the availability of a large cancer cohort subjected to WGS by The Cancer Genome Atlas (TCGA) consortium, we map somatic SVs in 600 tumors across 18 different cancer types and determine relationships between SVs, CNAs, and mRNA expression. We compare SV breakpoints with those from microarray-based CNA data to evaluate and optimize tools and parameters for SV detection, which additionally gives insights into the structural basis of CNAs. We next investigate relationships between SVs and changes in gene expression levels, both in the context of gene fusions as well as SVs affecting putative regulatory regions near TSSs. Finally, we combine breakpoints determined from WGS and RNA-sequencing (RNA-seq) data to detect high-confidence fusion genes across this large cohort.
Results
CNA-Based Evaluation of SV Detection Methodology. We first noted large discrepancies, for example in terms of SV types, when Significance Structural changes in chromosomes can alter the expression and function of genes in tumors, an important driving mechanism in some tumors. Whole-genome sequencing makes it possible to detect such events on a genome-wide scale, but comprehensive investigations are still missing. Here, enabled by a massive amount of whole-genome sequencing data generated by The Cancer Genome Atlas consortium, we map somatic structural changes in 600 tumors of diverse origins. At a global level, we find that such events often contribute to altered gene expression in human cancer, and also highlight specific events that may have functional roles during tumor development.
applying several available tools for SV detection to WGS data from TCGA tumor/normal pairs (Fig. 1A) , and therefore sought to carefully evaluate multiple options. A general problem in assessing SV results is the lack of true positive data for comparison (19) . To partially overcome this problem, we made use of orthogonal results in the form of CNA profiles from the Affymetrix SNP6 microarray platform (SI Methods). CNAs arise as a consequence of somatic SVs in the genome, and segmented CNA data therefore provide a true positive subset. Although this subset is incomplete, an ideal experimental and computational pipeline should essentially be able to detect all CNA breakpoints.
We applied four available tools, BreakDancer (20) , SVDetect (21), DELLY (22) , and Meerkat (11) , to high-coverage WGS data from 200 TCGA tumors of diverse origins, and quantified overlaps between SV and CNA breakpoints (<15-kb tolerance). To reduce the computational complexity, only a single chromosome (chr) was considered in this analysis (chr8). To also address the specificity of the methods, we investigated overlaps with a set of randomized CNA breakpoints that maintained a similar positional distribution across the genome (SI Methods). SVDetect had the highest sensitivity score (35%), followed by Meerkat (29%) (Fig. 1B) . However, Meerkat performed considerably better than SVDetect in terms of specificity (Fig. 1B) . Additionally, Meerkat performed favorably compared with the other methods when applied to 11 complete tumor genomes of diverse origins (Fig.  S1 ), and therefore we chose Meerkat for SV detection.
A Map of Somatic SVs Across 600 Tumor Genomes. We next used high-coverage WGS data from TCGA to map somatic SVs in 600 tumors across 18 cancer types (Dataset S1), and combined these results with somatic CNA (Affymetrix SNP6 microarrays) and expression (RNA-seq) data from the same samples. In total, 51,446 somatic SVs were identified (on average 87 events per sample). Of these, 36,382 were intrachromosomal (13,745 deletions, 13,335 tandem duplications, and 9,302 inversions), whereas 14,953 were interchromosomal translocations. The number of SVs and the relative distribution between SV classes varied considerably within and across cancer types ( Fig. 2A) .
Confirming previous data (10, (23) (24) (25) , breast (BRCA), ovarian (OV), and lung squamous (LUSC) tumors had a large number of SVs (>100 SVs per sample on average). Likewise, this number was high in uterine (UCEC) and stomach (STAD) tumors (107 and 125 per sample, respectively). Few SVs were found in copy number stable cancers such as thyroid carcinoma (THCA) (26) (∼8 per sample on average). Similarly, clear cell and chromophobe kidney carcinomas (KIRC and KICH) and low-grade glioma (LGG) tumors exhibited a small number of SVs ( Fig. 2A) .
We next investigated the relationship between somatic CNA and SV breakpoints. On average, 34% of CNA breakpoints (segments with absolute log 2 amplitude ≥0.3, SNP6 platform) detected across all 600 tumors were confirmed in the SV data. Overlaps were reduced in CNA stable tumors such as KICH, which are dominated by arm-level events and therefore may lack breakpoints detectable by WGS (Fig. 2B ). Absolute numbers of CNA and SV breakpoints were strongly correlated across tumors (Pearson's r = 0.81; Fig. 2C ). However, a small number of samples had elevated CNAs not reflected in the SV data ( Fig.  2C) , again explainable by the predominance of arm-level changes in these tumors (Fig. S2) . These results further support the validity of the SV data and show that both approaches are effective for quantifying overall chromosomal instability.
The overlap between CNA and SV data at the level of complete events (for example, both breakpoints for an amplification segment) was considerably lower (∼10%) compared with breakpoint-level overlaps. In many cases, this was explained in the SV data by a more complex structural basis than immediately evident from CNA profiles. Examples include apparent closely spaced large copy number deletion segments, revealed by the SV data to be due to a large (for example, whole-chromosome) deletion event superimposed on several small-amplitude-neutralizing tandem duplications (Fig. 2D) . Similarly, apparent clustered copy number amplification segments could sometimes be explained by a larger duplication in combination with several small deletions (Fig. 2E ). These results emphasize that care needs to be taken when drawing conclusions about structural chromosomal changes based on CNA data alone.
Of all CNA deletion segments (log 2 amplitude ≤−0.3) with a clear correspondence in the SV data, we found that 97% were categorized as deletions in the SV analysis (Fig. 2F) . Likewise, 90% of amplified regions were due to tandem duplication, whereas only 5% each overlapped with deletions or inversions.
Global Impact of Somatic SVs on Tumor mRNA Levels. For somatic SVs to be functional in cancer, they need to have an influence on transcription in some way, by altering mRNA structures or levels. We found that a large fraction (56%) of SV breakpoints were in genic regions, and that on average 112 genes per sample overlapped with at least one SV breakpoint, showing that SVs have considerable potential to alter tumor transcriptional output. A known mechanism for gene activation by SVs is the swapping of strong and weak promoters in the context of gene fusions. This is described for many individual genes, both with and without alteration of the protein-coding region (6, 27, 28) , but it remains unclear to what extent such events have a measurable global influence on tumor expression profiles.
Based on the SV data, we identified local rearrangements predicted to result in a fusion gene involving a strong promoter juxtaposed to a normally weakly expressed gene. We thus considered only gene pairs where the 5′ partner was expressed at a considerably higher average level within a given cancer type (greater than fourfold difference; SI Methods). We found that these criteria were often predictive of strong induction of the 3′ fusion partner: In 62/313 cases (20%), we observed induction of the 3′ partner above threefold in the structurally affected tumor compared with other tumors of the same cancer type (Fig. 3A) . This should be compared with only 8% and 3% for fusions involving incorrect gene orientation or a weakly expressed promoter, respectively ( Fig. 3A ; P = 1.1e-5 compared with incorrect orientation, P = 2.7e-7 compared with weak promoters, and BDancer SVDetect
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CNAs detected by SV tools (%) The fraction of CNA breakpoints overlapping with SV breakpoints was used as a proxy to determine the sensitivity of each tool (red bars). Randomized CNA breakpoints were used to assess the specificity of each tool (blue bars). P = 1.3e-6 compared with randomly picked cases; two-sided Kolmogorov-Smirnov test). Among the 62 cases showing induced expression were several confirmatory observations (Fig. S3) , including prominent activation of ERG in prostate cancer (29) as well as RET (30) and ALK (31) in THCA, by fusion with strong promoters from TMPRSS2, CCDC6, and STRN, respectively. Notable was strong (8.1-fold relative mean) mRNA induction of protein kinase C beta (PRKCB) through fusion with USP7, a highly expressed deubiquitinase, in colorectal carcinoma (COAD). PRKCB is a protein kinase linked to tumor growth and survival (32) that is druggable by the small-molecule inhibitor enzastaurin (33) . Although fusions involving PRKCB were recently detected in fibrous histiocytoma (34), they have not been described in COAD. Additionally, among the induced transcripts were several long noncoding RNAs (lncRNAs), including the intergenic RP11-521D12.1, strongly (39.9-fold) induced through fusion with ASAP2 in BRCA. Although the functional relevance remains to be established, this establishes promoter swapping as a mechanism for activation of lncRNAs in cancer.
A few recent studies show that structural rearrangements can contribute to transcriptional activation through shuffling of cisregulatory elements near the TSS of genes, without altering mRNA structure (35, 36) . This has been described in individual cases, but the impact on a more global scale remains unknown. To investigate this, we identified cases of genes being affected by upstream SVs (−10 to 0 kb from the TSS). We next considered the relative expression levels for these genes in affected samples compared with unaffected samples of the same cancer type while avoiding confounding effects from copy number changes and chromothripsis (SI Methods and Fig. S4 ). Cases with SVs in a region −110 to 100 kb upstream, or randomly picked cases, were considered as controls. We found that SV-affected genes/cases showed a weak trend toward overall increased mRNA levels ( Fig. 3B ; P = 0.069 and P = 0.0099, respectively, compared with the control sets). Although it remains to be determined to what extent the observed events are under positive selection, the results suggest upstream SVs may often contribute to transcriptional activation of genes in human tumors.
Notably, among top cases showing increased expression in relation to upstream SVs (40 cases above fourfold) was telomere reverse transcriptase (TERT) in two different cancers, KICH and KIRC (Fig. S5) . The data from KICH, where TERT upstream SVs were found in two samples with high TERT mRNA levels, confirm recently published results (7) (Fig. 3C) . In KIRC, the sample with the highest TERT expression also harbored an upstream SV, whereas an additional affected sample lacked mRNA elevation in this cancer (Fig. 3D) . Although not considered in the global screen due to simultaneous copy number gain, TERT upstream SVs were found also in one rectal adenocarcinoma (READ) and one melanoma (SKCM) sample (Fig. 3 E and F) , the latter notably lacking TERT promoter mutations. These results further support a role for upstream SVs in activation of TERT in cancer. Recent studies have relied on RNA-seq data to detect fusion genes in comprehensive tumor materials (37, 38) . However, similar to SV analysis, RNA-seq-based fusion detection is prone to both false positives and negatives (39) , for example due to read-mapping issues or misinterpreted germ-line events (40) . Therefore, we explored whether fusion gene detection can be improved by combining RNA and DNA data.
We applied FusionCatcher (41) to identify fusion transcripts in 431/600 samples with available paired-end RNA-seq data. In total, 9,657 fusions (on average 22.4 per sample) were reported, of which 1,467 were in-frame (Dataset S2). In parallel, we annotated all genomic SV breakpoints and identified 9,854 predicted gene fusions, of which 740 were inversions, 1,240 were deletions, 2,511 were duplications, and 5,363 were interchromosomal translocations (Fig. 4A ). Of these, 5,209 (52%) involved genes fused in the correct orientation, thus having the potential to produce a fusion transcript. We found that only 299 unique pairs of genes were detected in both DNA and RNA data, of which 97 were in-frame according to FusionCatcher (Fig. S6) . In this high-confidence set with dual DNA/RNA support, there were 78 genes recurrently involved in fusions in more than one sample (Table S1) . Next, we evaluated the two approaches, either alone or in combination, by investigating the enrichment of known cancer drivers in the Cancer Gene Census (CGC) database among the top recurrently fused genes (42) . We found that neither method alone showed notable CGC enrichment, although the SV-based analysis performed slightly better (Fig. 4B) . However, combining both approaches resulted in a notable CGC enrichment among top-scoring genes, with 14 of the 78 recurrently fused genes (18%) being listed in the CGC (random expectation ∼2.5%). This suggests that DNA and RNA approaches to fusion gene detection complement each other, such that a combination of both provides more relevant results.
In the set of high-confidence detections with dual DNA/RNA support (Fig. S6) were several known functional fusions, including TMPRSS2-ERG in 6/20 prostate adenocarcinoma tumors (PRAD) and RET-CCDC6 in THCA (2/34 tumors). Results also included EIF2AK4 fused to BUB1B, a mitotic checkpoint kinase, by a deletion in one PRAD tumor, with strong transcriptional induction of BUB1B in this sample (Fig. 4C) .
Novel Mechanism for Nuclear Factor, Erythroid 2 Like 2 Activation in
Cancer. Notable among the high-confidence fusions was paired box 8 (PAX8) fusing with nuclear factor, erythroid 2 like 2 (NFE2L2) in one THCA tumor, revealed by the SV data to be due to tandem duplication on chromosome 2 (Fig. 5A ). This event was associated with potent NFE2L2 transcriptional activation (Fig. 5B) as well as loss of the KEAP1 interaction domain in NFE2L2 (Fig. 5A) . NFE2L2 (NRF2) is a transcription factor that coordinates the cellular response to oxidative stress, which is activated in some tumors by mutations that disrupt interaction with its inhibitor KEAP1 (43). However, NFE2L2 fusions involving loss of the KEAP1 interaction domain have not been described, and the result is thus suggestive of a novel mechanism for NFE2L2 activation in cancer.
To further evaluate the PAX8-NFE2L2 fusion, we investigated the expression of known target genes downstream of NFE2L2. We found that known NFE2L2 targets were strongly induced in the tumor that carried the PAX8-NFE2L2 fusion, supporting its function as a potent activator of the NFE2L2 transcriptional program (Fig. 5C) . By considering an expanded set of THCA tumors with available exome sequencing data, we identified one tumor with a KEAP1 mutation, likewise associated with strong induction of NFE2L2 target mRNAs (Fig. 5C ). This further supports that NFE2L2 activation may contribute to tumorigenesis in some thyroid carcinomas.
We next synthesized the PAX8-NFE2L2 fusion transcript and cloned it into a lentiviral vector (Fig. S7) , and used this to overexpress it in the murine prostate adenocarcinoma cell line TRAMP-C1 (SI Methods). We used high-coverage RNA sequencing (>30 million reads per sample) to compare the expression profiles of cells expressing the PAX8-NFE2L2 fusion transcript with cells transduced with an empty vector. We observed a prominent transcriptional response dominated by inductions (534 induced and 215 repressed genes at q < 0.01; Fig. 5D ). To identify affected pathways, we next performed gene set enrichment analysis using GSEA (44) . Whereas no gene sets were significantly down-regulated, four sets were enriched among induced genes (adjusted P < 0.05; Fig. 5E ). Notably, these included experimentally determined targets of NFE2L2 ("transcriptional activation by NRF2"; Fig. 5F ), as well as "glutathione metabolism," "oxidative stress," and "arylhydrocarbon receptor" signaling, all of which are known to be regulated by NFE2L2 (43, 45) . Induction of the canonical NFE2L2 targets Gclc and Gclm was confirmed by quantitative RT-PCR (2.4-and 3.1-fold, respectively; P < 0.022), further showing that the PAX8-NFE2L2 fusion protein is a capable activator of NFE2L2 target mRNAs (Fig. 5G) .
Discussion
In the present study, we used an integrative workflow to analyze structural rearrangements in 600 tumors from 18 different cancer types. We rely on coanalysis of somatic CNA and SV data to optimize tools and parameters for SV detection, and to provide insights into the general structural basis of CNAs in tumors. Further coanalysis with RNA-seq data provided insights into the overall influence of SVs on gene expression in tumors.
Surprisingly, although there was a clear correlation between the number of CNA breakpoints and SV breakpoints seen in each tumor, only 34% of copy number breakpoints had correspondence in the SVs detected by WGS. It is likely that this partly can be explained by limited sensitivity in detecting SV breakpoints, for example due to insufficient read coverage in some regions. However, another contributing factor could be false positives or positional uncertainties arising from the circular binary segmentation algorithm used for detecting CNA breakpoints in array-based copy number data.
TERT is a subunit of telomerase essential for telomere maintenance and long-term proliferation potential of cancer cells. Both somatic promoter mutations (46) (47) (48) and copy number gains are known to contribute to TERT activation in tumors. Recent data from KICH suggest that also SVs in the promoter of TERT could be important (7). Our results extend this to additional cancers, thus more firmly establishing regulatory SVs as a mechanism for TERT mRNA induction.
Earlier studies have emphasized large discrepancies between different callers for detecting fusions in RNA-seq data and that false positive rates are high (39) . This should contribute to the limited overlap observed here between DNA-and RNA-based fusion predictions. Additionally, read-through transcription events may produce fusion transcripts involving neighboring genes, which have no correspondence in the SV data, and some genomic fusion may not be expressed, further reducing overlaps. Although both DNA and RNA data have limitations when it comes to detecting fusions, we found that a combination of the two data types reduced the noise inherent to each approach. This is in agreement with recent studies that combine DNA and RNA evidence to improve detection of gene fusions (49, 50) .
BUB1B encodes a mitotic checkpoint kinase also known as BUBR1 that ensures proper chromosome segregation by slowing down mitosis (51) . Hemizygous loss in mice results in increased susceptibility to carcinogen-induced colon cancer development (52) and accelerated aging (53) . On the other hand, elevated expression of BUB1B has also been associated with cancer progression (54) , and overexpression of Bub1b in mice results in tumorigenesis (55) . Fusions involving this gene have not been previously described, and the functional relevance of the EIF2AK4-BUB1B fusion found here deserves further investigation.
NFE2L2 or KEAP1 mutations, indicative of activation of the NFE2L2/NRF2 pathway that coordinates the cellular response to oxidative stress, are common in some cancers, including lung adenocarcinoma, but are uncommon in THCA. However, a recent study established that the NFE2L2 pathway is frequently altered in THCA through other mechanisms, including KEAP1 promoter hypermethylation (56) . Our results in THCA suggest an additional way of activating NFE2L2, whereby a fusion gene is formed that lacks the inhibitory KEAP1 interaction domain. This further establishes that NFE2L2 activation is important in THCA, and suggests a novel mechanism for activation of NFE2L2 in cancer.
In summary, by integrative analysis of genomic and transcriptomic data from a large tumor cohort, we provide multiple insights into structural rearrangements and their effects on gene expression in human cancer.
Methods
WGS data from 600 TCGA tumors were analyzed for somatic SVs using Meerkat (11) . Gene expression levels were quantified as described previously (47) . Fusions N F E 2 L 2 P = 4.5e-13 P = 3.4e-13 P = 7.8e-13 P =1.5e-22 Expression levels are shown relative to ubiquitin (mUb). P values were determined using Student's t test. Bars indicate the mean, and error bars indicate SD.
